In line with this, antibodies targeting human CD39/CD73 membrane-associated or soluble forms were shown to reduce tumor growth by boosting T-cell antitumor responses in syngeneic mouse models implanted in different tumor cell lines (MC38, MCA205, B16F10) [85]. This evidence concerns the gene ENTPD1 and neoplasm.